nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Readiness
Report #NBU-AF438A45·Framework v5.9·Pipeline v0.4·Evaluated 16 Oct 2026·OECD: 3.1 Basic medicine (neurosciences)·Subfield: Neurology·Basis: Full text·Type: Narrative review

Friend or foe? Glial-vascular interactions in health and neurodegenerative disease.

McQuaid et al.McQuaid, Sewell, Montagne·2026·Pharmacological reviews·10.1016/j.pharmr.2026.100143 ↗

Primary claim

glial-vascular interactions within the NGVU serve as both essential physiological mechanisms and critical pathological contributors across the spectrum of NDDs.

Tentative · heterogeneous postmortem and preclinical evidence does not establish causal pathological contribution across the full disease spectrum
In brief

A cross-disease synthesis organizes glial-vascular mechanisms and research priorities, but its causal and therapeutic framing exceeds the evidence.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

Dysfunction of glial and vascular cells is increasingly recognized as a central feature of neurodegenerative diseases. Growing evidence points to disruptions in glial-vascular interactions, which are critical for maintaining the functions of the neurogliovascular unit throughout the lifespan, as key contributors to disease initiation and progression. However, the mechanisms governing this complex intercellular crosstalk and its potential role in disease pathogenesis remain incompletely understood. In this review, we summarize the current understanding of glial-vascular communication across health and disease, with a particular focus on Alzheimer disease, stroke, cerebral small vessel disease, Parkinson disease, Huntington disease, and multiple sclerosis. We highlight emerging cellular and molecular interactions of interest, outline major gaps in our understanding, and discuss innovative tools, including transcriptomics, which are reshaping the study of neurogliovascular dynamics. A central unresolved question is whether glial and/or vascular dysfunction represents the primary initiating event across neurodegenerative diseases, or whether these processes emerge in parallel through shared upstream drivers. Unraveling these interactions may ultimately reveal novel therapeutic opportunities for a broad range of neurodegenerative conditions. SIGNIFICANCE STATEMENT: Neurogliovascular unit interactions are fundamental to brain homeostasis, yet the molecular basis of this crosstalk and its disruption in neurodegeneration remains poorly understood. This review provides the first comprehensive synthesis of molecular mechanisms governing the Neurogliovascular unit interface across physiological and pathological conditions, integrating evidence from related disorders. By consolidating key signaling pathways, disease-associated alterations, and emerging experimental approaches, this review offers a unifying framework to guide biomarker development and therapeutic targeting.

Key Claims

Primary finding · Tentative

glial-vascular interactions within the NGVU serve as both essential physiological mechanisms and critical pathological contributors across the spectrum of NDDs.

heterogeneous postmortem and preclinical evidence does not establish causal pathological contribution across the full disease spectrum

Conclusion, first paragraph
Quote verified
Secondary · Tentative

a convergent cascade of NGVU dysfunction can be identified across conditions.

uneven disease coverage and partly predicted cell communication limit certainty in a shared mechanistic cascade

Glial–Vascular Interactions in Neurodegenerative Diseases, introductory paragraph; Fig. 3
Quote verified
Secondary · Tentative

the available evidence implicates astrocytic overexpression of VEGF-A as a central mechanistic axis linking glial dysfunction to vascular pathology in HD

a small body of mouse, patient-tissue, and iPSC studies limits the claim of a central disease mechanism

Huntington Disease, final paragraph
Quote verified
Secondary · Tentative

These antiamyloid antibodies demonstrate that modulating glial-vascular interactions can yield clinically meaningful outcomes in neurodegenerative conditions

clinical antibody outcomes do not establish glial-vascular modulation when their NGVU effects remain underexplored

Clinical Translation Success Stories, first paragraph
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Cross-disease organization reveals shared research questions

The disease sections compare recurring vascular and glial changes while identifying condition-specific gaps, including underexplored oligodendrocyte-vascular interactions.

↳ Glial–Vascular Interactions in Neurodegenerative Diseases; Figures 3–4

#methodological rigour

Mechanistic narrative engages selected counter-evidence directly

The BBB discussion includes microglial depletion without barrier loss, and later sections acknowledge failed trials and vascular consequences of removing microglia.

↳ Blood-Brain Barrier Maintenance; Novel Cellular and Molecular Strategies; Drug Delivery Systems for Neurogliovascular Unit Targeting

#application pathway

Methods roadmap links inference with function

Future Directions connects vascular-enriched sequencing and spatial approaches with barrier and hemodynamic measurements, providing a concrete route for testing candidate interactions.

↳ Glia and Vascular Cell Heterogeneity; Tools to Assess Glial–Vascular Crosstalk

Limitations

#methodological rigour

Literature selection remains undocumented beyond tables

Selection criteria are supplied for the illustrative therapeutic tables but not for the broad empirical synthesis, leaving the overall coverage boundaries unspecified.

↳ Introduction through Conclusion; Development of Glial–Vascular Targeted Therapeutics

#positioning

Therapeutic conclusions exceed acknowledged mechanistic knowledge

Anti-amyloid antibodies are presented as demonstrating successful glial-vascular modulation despite the same passage stating that their NGVU effects remain underexplored. Table 1 and its narrative also disagree on development-stage distributions.

↳ Clinical Translation Success Stories; Table 1; Development of Glial–Vascular Targeted Therapeutics

#reporting

Causal framing exceeds heterogeneous disease evidence

The Conclusion attributes disease onset and progression to disrupted interactions, while the Abstract and disease sections leave causal ordering unresolved. Postmortem observations and predictive interaction analyses cannot establish that broad causal proposition.

↳ Abstract; Parkinson Disease; Tools to Assess Glial–Vascular Crosstalk; Conclusion

Does this match your read? Add your assessment ↓

Nabu Commentary

The cross-disease structure and Figures 1–4 make the physiological and pathological framework traceable, while Future Directions supplies a concrete program for functional validation. The synthesis has no general literature-selection account, limiting confidence in how the evidence base was assembled. Positioning is more constrained because Clinical Readiness Success Stories claims demonstrated glial-vascular benefit immediately after acknowledging underexplored NGVU effects, and predictive communication caveats do not consistently temper disease-level interpretations. These limitations leave the review more useful for research orientation than for establishing causal mechanisms or guiding treatment.

Check another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Study Quality

Sound3.2

Confidence medium
Contribution
3.4

The review integrates glial-vascular mechanisms across six conditions and identifies shared pathways and disease-specific research gaps. Its advance remains incremental, with causal and therapeutic claims extending beyond the heterogeneous evidence assembled.

Glial–Vascular Interactions in Neurodegenerative Diseases; Figures 3–4; Future Directions
Methodological Rigour
3.2

The argument connects cellular functions, disease observations, and experimental approaches while engaging some counter-evidence. The absence of a general source-identification and selection account limits assessment of coverage and carries the already-priced methodological deduction.

Introduction through Conclusion; Blood-Brain Barrier Maintenance; Development of Glial–Vascular Targeted Therapeutics
Reporting
3.5

Repeated health-to-disease organization and figures make the argument navigable. The Conclusion's disease-onset language can nevertheless lead readers to infer causal certainty that the body does not establish.

Figures 1–4; Abstract; Conclusion, first paragraph

"contributing to disease onset and progression"

Positioning
2.7

The review engages recent primary work and discusses unresolved causality and methodological constraints. Its clinical-success interpretation contradicts its own qualification about NGVU engagement, while predictive-interaction caveats do not sufficiently constrain parts of the disease synthesis.

Clinical Translation Success Stories; Tools to Assess Glial–Vascular Crosstalk; Huntington Disease

"their impact on the NGVU remains underexplored"

Reliability

Caveats4 of 4 checks


Results checkNoted

One reported value does not reconcile, but the key claims do not rest on it.

Reporting and transparencyNoted

Citation assignments differ between the natalizumab table entry and clinical narrative, and between repeated descriptions of HD pericyte and iPSC evidence; the supplied text does not establish which assignments are correct.

Conflict of interest: declared

Reference IntegrityClean

240 references in manuscript 239 of 239 checkable references found in an index 1 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Readiness

Where this paper’s evidence sits on the path from initial observation to real-world use.

Mechanistic

The synthesis maps candidate targets and a mixed-stage therapeutic landscape rather than providing deployment-ready guidance. Causal mechanisms, intervention windows, patient selection, and preservation of homeostatic function remain unresolved.

Development of Glial–Vascular Targeted Therapeutics; Conclusion
Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Impact of Apolipoprotein E4 on blood-brain barrier integrity in target replacement murine models: a systematic review and meta-analysis

    Laing, Fialova, Wardlaw, et al. · 2026 · Clinical medicine

    Primary claim

    APOE4 mice showed a consistent reduction in CBF associated with APOE4 genotype (SMD = -2.87, 95% CI: -5.14 to -0.604, df = 2.66)

    Tentative
    Study quality
    Limited2.8
    Reliability
    Caveats
  2. Photobiomodulation restores blood-brain barrier integrity after hypoxia via endothelial von Willebrand factor modulation in a humanised tricellular transwell model

    Domocos, Bragin, Shanbhag, et al. · 2026 · Neurology and psychiatry

    Primary claim

    Hypoxia significantly reduced transendothelial electrical resistance (TEER), whereas PBM restored barrier function in endothelial monocultures and tri-cultures.

    Supported
    Study quality
    Limited2.7
    Reliability
    Caveats
  3. Dysregulated TIE-2 expression is associated with blood-brain barrier leakiness and Alzheimer's disease-related neuropathology

    Ince, Van Hulle, Kollmorgen, et al. · 2026 · Clinical medicine

    Primary claim

    CSF soluble TIE-2 was elevated in AD biomarker+ve individuals and correlated positively with CSF t-tau and p-tau, and markers of BBB leakiness, neuronal injury, and neuroinflammation.

    Tentative
    Study quality
    Limited2.5
    Reliability
    Caveats

How the rubric works →